# The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

> **NCT00243347** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 19 (actual)

## Conditions studied

- Carcinoma
- Non-Small-Cell Lung Carcinoma
- Head and Neck Neoplasms

## Interventions

- **DRUG:** AZD2171

## Key facts

- **NCT ID:** NCT00243347
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-05
- **Final completion:** 2009-07
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2013-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00243347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00243347, "The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00243347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*